These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Taccetti G; Bianchini E; Cariani L; Buzzetti R; Costantini D; Trevisan F; Zavataro L; Campana S; Thorax; 2012 Oct; 67(10):853-9. PubMed ID: 22379071 [TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants. Ramchandani M; Robinson D J Control Release; 1998 Jul; 54(2):167-75. PubMed ID: 9724903 [TBL] [Abstract][Full Text] [Related]
24. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study. Stass H; Delesen H; Nagelschmitz J; Staab D J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456 [TBL] [Abstract][Full Text] [Related]
25. Topical ciprofloxacin treatment of Pseudomonas keratitis in rabbits. O'Brien TP; Sawusch MR; Dick JD; Gottsch JD Arch Ophthalmol; 1988 Oct; 106(10):1444-6. PubMed ID: 3140772 [TBL] [Abstract][Full Text] [Related]
26. Osteomyelitis of the clavicle following to a pacemaker implantation. Mugnai G; Pesarini G; Vassanelli C Europace; 2014 Nov; 16(11):1618. PubMed ID: 24965014 [No Abstract] [Full Text] [Related]
27. Pubic osteomyelitis due to Pseudomonas aeruginosa. de Miguel J; Collazos J; Ayarza R; Abaitua JM; Quilez J Clin Infect Dis; 1993 Sep; 17(3):515-6. PubMed ID: 8218704 [No Abstract] [Full Text] [Related]
28. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa. Rhee MK; Kowalski RP; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ Am J Ophthalmol; 2004 Aug; 138(2):226-30. PubMed ID: 15289131 [TBL] [Abstract][Full Text] [Related]
29. Pseudomonas Aeruginosa Osteomyelitis of the Pubic Bone: A Case Report. Siyahkali SJM; SeyedAlinaghi S; Samaei M; Taj L Infect Disord Drug Targets; 2018; 18(2):177-179. PubMed ID: 28707596 [TBL] [Abstract][Full Text] [Related]
30. Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection. VanDevanter DR; Gonda I; Dahms J; Cipolla D; Davis AM; Chalmers JD; Froehlich J Clin Microbiol Infect; 2019 Dec; 25(12):1532-1538. PubMed ID: 31035017 [TBL] [Abstract][Full Text] [Related]
31. In vivo application of biodegradable controlled antibiotic release systems for the treatment of implant-related osteomyelitis. Gürsel I; Korkusuz F; Türesin F; Alaeddinoglu NG; Hasirci V Biomaterials; 2001 Jan; 22(1):73-80. PubMed ID: 11085386 [TBL] [Abstract][Full Text] [Related]
32. Topical ciprofloxacin versus topical fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis. Lauffenburger MD; Cohen KL Cornea; 1993 Nov; 12(6):517-21. PubMed ID: 8261784 [TBL] [Abstract][Full Text] [Related]
33. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration. Strukova EN; Portnoy YA; Zinner SH; Firsov AA J Antimicrob Chemother; 2016 Mar; 71(3):678-84. PubMed ID: 26626718 [TBL] [Abstract][Full Text] [Related]
34. Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance. Sousa AM; Monteiro R; Pereira MO Int J Med Microbiol; 2018 Dec; 308(8):1053-1064. PubMed ID: 30377031 [TBL] [Abstract][Full Text] [Related]
35. Comparative trial of different anti-bacterial combinations with propolis and ciprofloxacin on Pseudomonas keratitis in rabbits. Onlen Y; Tamer C; Oksuz H; Duran N; Altug ME; Yakan S Microbiol Res; 2007; 162(1):62-8. PubMed ID: 16904302 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections. Giamarellou H; Galanakis N; Dendrinos C; Stefanou J; Daphnis E; Daikos GK Eur J Clin Microbiol; 1986 Apr; 5(2):232-5. PubMed ID: 2941288 [TBL] [Abstract][Full Text] [Related]
37. Oral ciprofloxacin treatment of Pseudomonas aeruginosa osteomyelitis. Dan M; Siegman-Igra Y; Pitlik S; Raz R Antimicrob Agents Chemother; 1990 May; 34(5):849-52. PubMed ID: 2360823 [TBL] [Abstract][Full Text] [Related]
38. Controlled delivery of ciprofloxacin and ivacaftor via sinus stent in a preclinical model of Pseudomonas sinusitis. Lim DJ; McCormick J; Skinner D; Zhang S; Elder JB; McLemore JG; Allen M; West JM; Grayson JW; Rowe SM; Woodworth BA; Cho DY Int Forum Allergy Rhinol; 2020 Apr; 10(4):481-488. PubMed ID: 31872532 [TBL] [Abstract][Full Text] [Related]
39. Successful treatment of multi-resistant Pseudomonas aeruginosa osteomyelitis after allogeneic bone marrow transplantation with a combination of colistin and tigecycline. Stanzani M; Tumietto F; Giannini MB; Bianchi G; Nanetti A; Vianelli N; Arpinati M; Giovannini M; Bonifazi F; Bandini G; Baccarani M J Med Microbiol; 2007 Dec; 56(Pt 12):1692-1695. PubMed ID: 18033842 [TBL] [Abstract][Full Text] [Related]
40. In-vitro evaluation of a ciprofloxacin- and ivacaftor-coated sinus stent against Pseudomonas aeruginosa biofilms. Cho DY; Lim DJ; Mackey C; Weeks CG; Garcia JAP; Skinner D; Zhang S; McCormick J; Woodworth BA Int Forum Allergy Rhinol; 2019 May; 9(5):486-492. PubMed ID: 30702211 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]